# Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

Study · id `cardio:ct-nct04951856` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04951856](<https://clinicaltrials.gov/study/NCT04951856>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04951856

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 2166 participants.

## Technical summary

Registry record NCT04951856. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2026-05-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2166 participants (planned count; ClinicalTrials.gov record NCT04951856, source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)
- Started: 2021-09-29 (actual) (ClinicalTrials.gov record NCT04951856, source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2026-05-22 (anticipated) (ClinicalTrials.gov record NCT04951856, source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)
- Completion: 2028-05-22 (anticipated) (ClinicalTrials.gov record NCT04951856, source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04951856, source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04951856-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
- Acronym: AMUNDSEN
- Condition: STEMI - ST Elevation Myocardial Infarction
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Intervention (Drug): Evolocumab 140 MG/ML
- Intervention (Drug): Standard of care (SOC)
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Action Research Group
- Collaborator class: OTHER
- Collaborator: Amgen
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Action Research Group (`cardio:org-action-research-group`)
- Registry lists this organization as a collaborator: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: b12c56098b8fc92ef269eb469bd42b17f69114733438e9e21e9ce28b07a0938f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
